Skip to content 
Vicore Pharma AB provides pharmaceutical products. The Company offers products for the treatment of anti-inflammation, nerve generation, and cardiovascular diseases. Vicore Pharma Holding is based in Sweden. more
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | 109.35M | 3.82M | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":3.49,"profit":true}] | |
| Cost of Revenue | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Gross Profit | - | - | 109.35M | 3.82M | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":3.49,"profit":true}] | |
| Gross Margin | - | - | 100.00% | 100.00% | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |
| Operating Expenses | 287.49M | 320.89M | 299.71M | 458.26M | [{"date":"2022-12-31","value":62.74,"profit":true},{"date":"2023-12-31","value":70.02,"profit":true},{"date":"2024-12-31","value":65.4,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |
| Operating Income | (287.49M) | (320.89M) | (190.36M) | (454.44M) | [{"date":"2022-12-31","value":-28749400000,"profit":false},{"date":"2023-12-31","value":-32088900000,"profit":false},{"date":"2024-12-31","value":-19036000000,"profit":false},{"date":"2025-12-31","value":-45444500000,"profit":false}] | |
| Total Non-Operating Income/Expense | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Pre-Tax Income | (288.81M) | (311.33M) | (168.89M) | (477.47M) | [{"date":"2022-12-31","value":-28880600000,"profit":false},{"date":"2023-12-31","value":-31132600000,"profit":false},{"date":"2024-12-31","value":-16889000000,"profit":false},{"date":"2025-12-31","value":-47747400000,"profit":false}] | |
| Income Taxes | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Income After Taxes | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Income From Continuous Operations | (288.42M) | (310.94M) | (168.63M) | (477.47M) | [{"date":"2022-12-31","value":-28842200000,"profit":false},{"date":"2023-12-31","value":-31094200000,"profit":false},{"date":"2024-12-31","value":-16863400000,"profit":false},{"date":"2025-12-31","value":-47747400000,"profit":false}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Net Income | (288.42M) | (310.94M) | (168.63M) | (477.47M) | [{"date":"2022-12-31","value":-28842200000,"profit":false},{"date":"2023-12-31","value":-31094200000,"profit":false},{"date":"2024-12-31","value":-16863400000,"profit":false},{"date":"2025-12-31","value":-47747400000,"profit":false}] | |
| EPS (Diluted) | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| VCRE | |
|---|---|
| Current Ratio | 12.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| VCRE | |
|---|---|
| ROA (LTM) | -28.12% |
| ROE (LTM) | -47.19% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| VCRE | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| VCRE | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 9492.79 |
| P/B | 37.80 |
| Price/FCF | NM |
| EV/R | 767.51 |
| EV/Ebitda | NM |
VICORE PHARMA HOLDING AB ADR (VCRE) share price today is $13.78
Yes, Indians can buy shares of VICORE PHARMA HOLDING AB ADR (VCRE) on Vested. To buy
Yes, you can purchase fractional shares of VICORE PHARMA HOLDING AB ADR (VCRE) via the Vested app. You can start investing in VICORE PHARMA HOLDING AB ADR (VCRE) with a minimum investment of $1.
You can invest in shares of VICORE PHARMA HOLDING AB ADR (VCRE) via Vested in three simple steps:
The 52-week high price of VICORE PHARMA HOLDING AB ADR (VCRE) is $17.8. The 52-week low price of VICORE PHARMA HOLDING AB ADR (VCRE) is $13.21.
The price-to-earnings (P/E) ratio of VICORE PHARMA HOLDING AB ADR (VCRE) is
The price-to-book (P/B) ratio of VICORE PHARMA HOLDING AB ADR (VCRE) is 37.80
The dividend yield of VICORE PHARMA HOLDING AB ADR (VCRE) is 0.00%
The market capitalization of VICORE PHARMA HOLDING AB ADR (VCRE) is $3.92B
The stock symbol (or ticker) of VICORE PHARMA HOLDING AB ADR is VCRE
Consider the share price of VICORE PHARMA HOLDING AB ADR as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether VICORE PHARMA HOLDING AB ADR has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in VICORE PHARMA HOLDING AB ADR shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the VICORE PHARMA HOLDING AB ADR stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of VICORE PHARMA HOLDING AB ADR and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that VICORE PHARMA HOLDING AB ADR stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
